New drug shows promise against rare salivary gland cancer
NCT ID NCT03781986
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called APG-115, alone or with chemotherapy, in people with a certain type of salivary gland cancer that has a normal p53 gene. The goal is to see if the drug can shrink tumors and to find the best dose with acceptable side effects. About 41 adults with advanced cancer that cannot be cured will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SALIVARY GLAND CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States